Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Eric DK. Engines of Creation. The Coming Era of Nanotechnology. Doubleday, NY, USA (1986).
  Google Scholar
• 2 Feynman RP. There's plenty of room at the bottom. Eng. Sci. 23(5), 22–36 (1960). •• The very first inkling of what would become the nanotechology revolution.
  Google Scholar
• 3 Devreese JT. Importance of nanosensors: Feynman's vision and the birth of nanotechnology. MRS Bull. 32(09), 718–725 (2007).
  CASGoogle Scholar
• 4 Qu X, Alvarez PJ, Li Q. Applications of nanotechnology in water and wastewater treatment. Water Res. 47(12), 3931–3946 (2013).
  Medline CASGoogle Scholar
• 5 Sawhney A, Condon B, Singh K, Pang S, Li G, Hui D. Modern applications of nanotechnology in textiles. Textile Res. J. 78(8), 731–739 (2008).
  CASGoogle Scholar
• 6 Chan CK, Peng H, Liu G et al. High-performance lithium battery anodes using silicon nanowires. Nat. Nanotechnol. 3(1), 31–35 (2008).
  Medline CASGoogle Scholar
• 7 Briggs BD, Knecht MR. Nanotechnology meets biology: peptide-based methods for the fabrication of functional materials. J. Phys. Chem. Lett 3(3), 405–418 (2012).
  Medline CASGoogle Scholar
• 8 Langer R, Weissleder R. Scientific discovery and the future of medicine. JAMA 313, 135–136 (2015).
  Medline CASGoogle Scholar
• 9 Coccia M, Wang L. Path-breaking directions of nanotechnology-based chemotherapy and molecular cancer therapy. Technol. Forecast. Soc. Change 94, 155–169 (2015).
  Google Scholar
• 10 Karimi M, Zare H, Bakhshian NA et al. Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine 11(5), 513–530 (2016).
  CASGoogle Scholar
• 11 Parpura V. Tissue engineering: nanoelectronics for the heart. Nat. Nanotechnol. 11(9), 738–739 (2016).
  Medline CASGoogle Scholar
• 12 Karimi M, Mirshekari H, Aliakbari M, Sahandi-Zangabad P, Hamblin MR. Smart mesoporous silica nanoparticles for controlled-release drug delivery. Nanotechnol. Rev. 5(2), 195–207 (2016).
  CASGoogle Scholar
• 13 Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Del. Rev. 58(14), 1456–1459 (2006). •• Important perspective concerning the emerging field of nanomedicine.
  Medline CASGoogle Scholar
• 14 Sayes CM, Aquino GV, Hickey AJ. Nanomaterial drug products: manufacturing and analytical perspectives. AAPS J. 19(1), 18–25 (2017).
  Medline CASGoogle Scholar
• 15 Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed. Nanotechnol. Biol. Med. 9(1), 1–14 (2013).
  CASGoogle Scholar
• 16 Dilnawaz F, Acharya S, Sahoo SK. Recent trends of nanomedicinal approaches in clinics. Int. J. Pharm. 538(1–2), 263–278 (2018).
  Medline CASGoogle Scholar
• 17 Ragelle H, Danhier F, Préat V, Langer R, Anderson DG. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin. Drug Deliv. 14(7), 851–864 (2017).
  Medline CASGoogle Scholar
• 18 Iyer R, Hsia CC, Nguyen KT. Nano-therapeutics for the lung: state-of-the-art and future perspectives. Curr. Pharm. Des. 21(36), 5233–5244 (2015).
  Medline CASGoogle Scholar
• 19 Desai PP, Rustomjee MT. Business potential of advanced drug delivery systems. Confocal Microscopy 23, 29 (2018).
  Google Scholar
• 20 Karimi M, Zangabad PS, Ghasemi A, Hamblin MR. Future perspectives and the global drug delivery systems market. In: Smart Internal Stimulus-Responsive Nanocarriers for Drug and Gene Delivery (Eds). Morgan & Claypool Publishers, CA, USA (2015).
  Google Scholar
• 21 Bhowmik D, Gopinath H, Kumar BP, Duraivel S, Kumar KS. Controlled release drug delivery systems. Pharma Innov. 1(10), (2012).
  Google Scholar
• 22 Nikalje AP. Nanotechnology and its applications in medicine. Med. Chem. 5, 81–89 (2015).
  Google Scholar
• 23 Yih T, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J. Cell. Biochem. 97(6), 1184–1190 (2006).
  Medline CASGoogle Scholar
• 24 Liu L, Ye Q, Lu M et al. A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs. Sci. Rep. 5, 10881 (2015).
  Medline CASGoogle Scholar
• 25 Balakumar K, Raghavan CV, Abdu S. Self nanoemulsifying drug-delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. Colloids Surf. B. Biointerfaces 112, 337–343 (2013).
  Medline CASGoogle Scholar
• 26 Karimi M, Sahandi Zangabad P, Baghaee-Ravari S, Ghazadeh M, Mirshekari H, Hamblin MR. Smart nanostructures for cargo delivery: uncaging and activating by light. J. Am. Chem. Soc. 139(13), 4584–4610 (2017). • Review about light activated drug-delivery using nanomaterials
  Medline CASGoogle Scholar
• 27 Bosetti R, Marneffe W, Vereeck L. Assessing the need for quality-adjusted cost–effectiveness studies of nanotechnological cancer therapies. Nanomedicine 8(3), 487–497 (2013).
  CASGoogle Scholar
• 28 Karimi M, Eslami M, Sahandi-Zangabad P et al. pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8(5), 696–716 (2016).
  Medline CASGoogle Scholar
• 29 Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Del. Rev. 66, 2–25 (2014). •• Good review about nanomedicines and cancer concentrating on targeting strategies.
  Medline CASGoogle Scholar
• 30 Karimi M, Moosavi Basri SM, Vossoughi M, Pakchin PS, Mirshekari H, Hamblin MR. Redox-sensitive smart nanosystems for drug and gene delivery. Curr. Org. Chem. 20(28), 2949–2959 (2016).
  CASGoogle Scholar
• 31 Sargent JF Jr. Nanotechnology: a policy primer (2016).
  Google Scholar
• 32 Hosseini M, Farjadian F, Makhlouf ASH. Smart stimuli-responsive nano-sized hosts for drug-delivery. In: Industrial Applications for Intelligent Polymers and Coatings. Hosseini M, Makhlouf ASH (Eds). Springer, Basel, Switzerland, 1–26 (2016).
  Google Scholar
• 33 Zhang M-Q, Wilkinson B. Drug discovery beyond the ‘rule-of-five’. Curr. Opin. Biotechnol. 18(6), 478–488 (2007).
  Medline CASGoogle Scholar
• 34 Ige PP, Baria RK, Gattani SG. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf. B. Biointerfaces 108, 366–373 (2013).
  Medline CASGoogle Scholar
• 35 Karimi M, Ghasemi A, Zangabad PS et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem. Soc. Rev. 45(5), 1457–1501 (2016).
  Medline CASGoogle Scholar
• 36 Zangabad PS, Karimi M, Mehdizadeh F et al. Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger. Nanoscale 9(4), 1356–1392 (2017).
  MedlineGoogle Scholar
• 37 Farjadian F, Moghoofei M, Mirkiani S et al. Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: set the bugs to work? Biotechnol. Adv. (2018). • Interesting review about using nanomaterial derived from bacterial structures as drug-targeting vehicles.
  MedlineGoogle Scholar
• 38 Junghanns J-UA, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 3(3), 295 (2008).
  Medline CASGoogle Scholar
• 39 Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J. Control. Release 172(1), 12–21 (2013).
  Medline CASGoogle Scholar
• 40 Wu Z, Wu Z-K, Tang H, Tang L-J, Jiang J-H. Activity-based DNA-gold nanoparticle probe as colorimetric biosensor for DNA methyltransferase/glycosylase assay. Anal. Chem. 85(9), 4376–4383 (2013).
  Medline CASGoogle Scholar
• 41 Crucho CIC, Barros MT. Polymeric nanoparticles: a study on the preparation variables and characterization methods. Mater. Sci. Eng. C 80(Suppl. C), 771–784 (2017).
  Medline CASGoogle Scholar
• 42 Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater. Sci. Eng. C 60(Suppl. C), 569–578 (2016).
  Medline CASGoogle Scholar
• 43 Lin G, Zhang H, Huang L. Smart polymeric nanoparticles for cancer gene delivery. Mol. Pharm. 12(2), 314–321 (2015).
  Medline CASGoogle Scholar
• 44 Guo B, Ma PX. Synthetic biodegradable functional polymers for tissue engineering: a brief review. Science China Chemistry 57(4), 490–500 (2014).
  Medline CASGoogle Scholar
• 45 Smith IO, Liu XH, Smith LA, Ma PX. Nano-structured polymer scaffolds for tissue engineering and regenerative medicine. Wiiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(2), 226–236 (2009).
  Medline CASGoogle Scholar
• 46 Akbarzadeh A, Rezaei-Sadabady R, Davaran S et al. Liposome: classification, preparation, and applications. Nanoscale Res. Lett. 8(1), 102 (2013).
  MedlineGoogle Scholar
• 47 Bang SH, Sekhon SS, Kim Y-H, Min J. Preparation of liposomes containing lysosomal enzymes for therapeutic use. Biotechnol. Bioprocess Eng. 19(5), 766–770 (2014).
  CASGoogle Scholar
• 48 Dubey V, Mishra D, Asthana A, Jain NK. Transdermal delivery of a pineal hormone: melatonin via elastic liposomes. Biomaterials 27(18), 3491–3496 (2006).
  Medline CASGoogle Scholar
• 49 Parmentier J, Hofhaus G, Thomas S et al. Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. J. Pharm. Sci. 103(12), 3985–3993 (2014).
  Medline CASGoogle Scholar
• 50 Wyrozumska P, Meissner J, Toporkiewicz M et al. Liposome-coated lipoplex-based carrier for antisense oligonucleotides. Cancer Biol. Ther. 16(1), 66–76 (2015).
  Medline CASGoogle Scholar
• 51 Mcintosh DP, Heath TD. Liposome-mediated delivery of ribosome inactivating proteins to cells in vitro. Biochim. Biophys. Acta 690(2), 224–230 (1982).
  Medline CASGoogle Scholar
• 52 Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticles. Int. J. Nanomed. 2(4), 595–607 (2007).
  Medline CASGoogle Scholar
• 53 Rasoulianboroujeni M, Kupgan G, Moghadam F et al. Development of a DNA-liposome complex for gene delivery applications. Mater. Sci. Eng. C 75, 191–197 (2017).
  Medline CASGoogle Scholar
• 54 Seleci M, Ag Seleci D, Scheper T, Stahl F. Theranostic liposome-nanoparticle hybrids for drug delivery and bioimaging. Int. J. Mol. Sci. 18(7), (2017). • Introduces the concept of hybrid nanomaterials for theranostics, simultaneous imaging and therapy.
  MedlineGoogle Scholar
• 55 Frey NA, Peng S, Cheng K, Sun S. Magnetic nanoparticles: synthesis, functionalization, and applications in bioimaging and magnetic energy storage. Chem. Soc. Rev. 38(9), 2532–2542 (2009).
  Medline CASGoogle Scholar
• 56 Reiner AT, Ferrer N-G, Venugopalan P, Lai RC, Lim SK, Dostálek J. Magnetic nanoparticle-enhanced surface plasmon resonance biosensor for extracellular vesicle analysis. Analyst 142(20), 3913–3921 (2017).
  Medline CASGoogle Scholar
• 57 Kolesnichenko V, Goloverda G, Kucheryavy P, Spinu L. Iron oxide nanoparticles with a variable size and an iron oxidation state for imaging applications. In: Nanotechnology in Medicine: From Molecules to Humans. Eniola-Adefeso L, Decuzzi P (Eds). ECI Symposium Series, LA, USA (2016). http://dc.engconfintl.org/nanotech_med/26.
  Google Scholar
• 58 Wang Y, Cui H, Li K et al. A magnetic nanoparticle-based multiple-gene delivery system for transfection of porcine kidney cells. PLoS ONE 9(7), e102886 (2014).
  MedlineGoogle Scholar
• 59 Lee RW, Shenoy DB, Sheel R. Chapter 2 – Micellar nanoparticles: applications for topical and passive transdermal drug delivery A2. In: Handbook of Non-Invasive Drug Delivery Systems. Kulkarni VS (Ed.). William Andrew Publishing, MA, USA, 37–58 (2010).
  Google Scholar
• 60 Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J. Drug Target. 13(1), 73–80 (2005).
  Medline CASGoogle Scholar
• 61 Zhang R, Saito R, Mano Y et al. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models. Drug Deliv. 23(8), 2780–2786 (2016).
  Medline CASGoogle Scholar
• 62 Sun L, Deng X, Yang X et al. Co-delivery of doxorubicin and curcumin by polymeric micelles for improving antitumor efficacy on breast carcinoma. RSC Adv. 4(87), 46737–46750 (2014).
  CASGoogle Scholar
• 63 Wang Y, Ding Y, Liu Z, Liu X, Chen L, Yan W. Bioactive lipids-based pH-sensitive micelles for co-delivery of doxorubicin and ceramide to overcome multidrug resistance in leukemia. Pharm. Res. 30(11), 2902–2916 (2013).
  Medline CASGoogle Scholar
• 64 Scott RW, Wilson OM, Crooks RM. Synthesis, characterization, and applications of dendrimer-encapsulated nanoparticles. J. Phys. Chem. B 109(2), 692–704 (2005).
  Medline CASGoogle Scholar
• 65 Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK. Dendimer-mediated solubilization, formulation development and in vitro-in-vivo assessment of piroxicam. Mol. Pharm. 6(3), 940–950 (2009).
  Medline CASGoogle Scholar
• 66 Zhou Z, D'Emanuele A, Attwood D. Solubility enhancement of paclitaxel using a linear-dendritic block copolymer. Int. J. Pharm. 452(1–2), 173–179 (2013).
  Medline CASGoogle Scholar
• 67 Manikkath J, Hegde AR, Kalthur G, Parekh HS, Mutalik S. Influence of peptide dendrimers and sonophoresis on the transdermal delivery of ketoprofen. Int. J. Pharm. 521(1–2), 110–119 (2017).
  Medline CASGoogle Scholar
• 68 Majoros IJ, Williams CR, Becker A, Baker JR Jr. Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(5), 502–510 (2009).
  Medline CASGoogle Scholar
• 69 Bharti C, Nagaich U, Pal AK, Gulati N. Mesoporous silica nanoparticles in target drug-delivery system: a review. Int. J. Pharm. Investig. 5(3), 124–133 (2015).
  Medline CASGoogle Scholar
• 70 Lin J-T, Liu Z-K, Zhu Q-L et al. Redox-responsive nanocarriers for drug and gene co-delivery based on chitosan derivatives modified mesoporous silica nanoparticles. Colloids Surf. B. Biointerfaces 155, 41–50 (2017).
  Medline CASGoogle Scholar
• 71 Portin L. Layer by Layer Assembly of the Polyelectrolyte on Mesoporous Silicon. Biosciences, University of Eastern Finland, Joensuu, Finland, 1–59 (2012).
  Google Scholar
• 72 Gary-Bobo M, Hocine O, Brevet D et al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int. J. Pharm. 423(2), 509–515 (2012).
  Medline CASGoogle Scholar
• 73 Janib SM, Moses AS, Mackay JA. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Del. Rev. 62(11), 1052–1063 (2010).
  Medline CASGoogle Scholar
• 74 Farjadian F, Ghasemi S, Heidari R, Mohammadi-Samani S. In vitro and in vivo assessment of EDTA-modified silica nano-spheres with supreme capacity of iron capture as a novel antidote agent. Nanomed. Nanotechnol. Biol. Med. 13(2), 745–753 (2017).
  CASGoogle Scholar
• 75 Farjadian F, Ahmadpour P, Samani SM, Hosseini M. Controlled size synthesis and application of nanosphere MCM-41 as potent adsorber of drugs: a novel approach to new antidote agent for intoxication. Microporous Mesoporous Mater. 213, 30–39 (2015).
  CASGoogle Scholar
• 76 Karimi M, Ghasemi A, Mirkiani S, Basri SMM, Hamblin MR. Carbon Nanotubes: Properties and Classification. Morgan & Claypool Publishers, CA, USA (2017).
  Google Scholar
• 77 Zanello LP, Zhao B, Hu H, Haddon RC. Bone cell proliferation on carbon nanotubes. Nano Lett. 6(3), 562–567 (2006).
  Medline CASGoogle Scholar
• 78 Yunok O, Jun OJ, Junghwan O. Photothermal-triggered control of sub-cellular drug accumulation using doxorubicin-loaded single-walled carbon nanotubes for the effective killing of human breast cancer cells. Nanotechnology 28(12), 125101 (2017).
  MedlineGoogle Scholar
• 79 Scheinberg DA, Mcdevitt MR, Dao T, Mulvey JJ, Feinberg E, Alidori S. Carbon nanotubes as vaccine scaffolds. Adv. Drug Del. Rev. 65(15), 10.1016/j.addr.2013.1007.1013 (2013).
  MedlineGoogle Scholar
• 80 Sanginario A, Miccoli B, Demarchi D. Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment. Biosensors (Basel) 7(1), (2017).
  MedlineGoogle Scholar
• 81 Wang JTW, Rubio N, Kafa H et al. Kinetics of functionalised carbon nanotube distribution in mouse brain after systemic injection: spatial to ultra-structural analyses. J. Control. Release 224, 22–32 (2016).
  Medline CASGoogle Scholar
• 82 Roman JA, Niedzielko TL, Haddon RC, Parpura V, Floyd CL. Single-walled carbon nanotubes chemically functionalized with polyethylene glycol promote tissue repair in a rat model of spinal cord injury. J. Neurotrauma 28(11), 2349–2362 (2011).
  MedlineGoogle Scholar
• 83 Jain S, Hirst D, O'Sullivan J. Gold nanoparticles as novel agents for cancer therapy. Br. J. Radiol. 85(1010), 101–113 (2012).
  Medline CASGoogle Scholar
• 84 Gholipourmalekabadi M, Mobaraki M, Ghaffari M et al. Targeted drug delivery based on gold nanoparticle derivatives. Curr. Pharm. Des. 23(20), 2918–2929 (2017).
  Medline CASGoogle Scholar
• 85 Tian L, Lu L, Qiao Y, Ravi S, Salatan F, Melancon MP. Stimuli-responsive gold nanoparticles for cancer diagnosis and therapy. J. Funct. Biomater. 7(3), 19 (2016).
  Google Scholar
• 86 El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 239(1), 129–135 (2006).
  Medline CASGoogle Scholar
• 87 Liao YH, Chang YJ, Yoshiike Y, Chang YC, Chen YR. Negatively charged gold nanoparticles inhibit Alzheimer's amyloid-β fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small 8(23), 3631–3639 (2012).
  Medline CASGoogle Scholar
• 88 Barathmanikanth S, Kalishwaralal K, Sriram M et al. Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice. J. Nanobiotechnol. 8(1), 16 (2010).
  MedlineGoogle Scholar
• 89 Leonavičienė L, Kirdaitė G, Bradūnaitė R et al. Effect of gold nanoparticles in the treatment of established collagen arthritis in rats. Medicina (Kaunas) 48(2), 91–101 (2012).
  MedlineGoogle Scholar
• 90 Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. Epma J. 4(1), 20 (2013).
  MedlineGoogle Scholar
• 91 Smith AM, Nie S. Semiconductor nanocrystals: structure, properties, and band gap engineering. Acc. Chem. Res 43(2), 190–200 (2010).
  Medline CASGoogle Scholar
• 92 Michalet X, Pinaud F, Bentolila L et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307(5709), 538–544 (2005).
  Medline CASGoogle Scholar
• 93 Hild W, Breunig M, Göpferich A. Quantum dots–nano-sized probes for the exploration of cellular and intracellular targeting. Eur. J. Pharm. Biopharm. 68(2), 153–168 (2008).
  Medline CASGoogle Scholar
• 94 Bawa R, Melethil S, Simmons WJ, Harris D. Nanopharmaceuticals: patenting issues and FDA regulatory challenges. SciTech Lawyer 5(2), 1–8 (2008).
  Google Scholar
• 95 Eaton MA. Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry. J. Control. Release 164(3), 370–371 (2012).
  Medline CASGoogle Scholar
• 96 Von Windheim J, Myers B. A lab-to-market roadmap for early-stage entrepreneurship. Transl. Mater. Res. 1(1), 16001–16001 (2014).
  Google Scholar
• 97 Bosetti R, Vereeck L. The impact of effective patents on future innovations in nanomedicine. Pharm. Patent Analyst 1(1), 37–43 (2012).
  Medline CASGoogle Scholar
• 98 Borges BJ, Carminati LS, Fernandes PM, Fernandes AaR. Regulatory framework of nanopharmaceuticals in developing countries: an analysis of the current rules in Brazil. In: Inorganic Frameworks as Smart Nanomedicines. Grumezescu A (Ed.). William Andrew Publishing, MA, USA, 605–639 (2018).
  Google Scholar
• 99 Conde J, Artzi N. Are RNAi and miRNA therapeutics truly dead? 33, 141–144 (2015).
  Google Scholar
• 100 Shapira P, Wang J. From lab to market? Strategies and issues in the commercialization of nanotechnology in China. Asian Bus. Manag. 8(4), 461–489 (2009).
  Google Scholar
• 101 Avorn J. The $2.6 billion pill – methodologic and policy considerations. N. Engl. J. Med. 372(20), 1877–1879 (2015).
  Medline CASGoogle Scholar
• 102 Dimasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
  MedlineGoogle Scholar
• 103 Milman J. Does it really cost $2.6 billion to develop a new drug? The Washington Post (2014). www.washingtonpost.com/news/wonk/wp/2014/11/18/does-it-really-cost-2-6-billion-to-develop-a-new-drug/?utm_term=.42007dcc67d9.
  Google Scholar
• 104 Bhattacharya I, Heatherington A, Barton J. Applying the best of oncology drug development paradigms to the non-malignant space. Drug Discov. Today 21(12), 1869–1872 (2016).
  MedlineGoogle Scholar
• 105 Dimasi JA, Grabowski HG, Hansen RW. The cost of drug development. N. Engl. J. Med. 372(20), 1972–1972 (2015).
  MedlineGoogle Scholar
• 106 Erkekoglu P, Kocer-Gumusel B. Toxicity assessment of nanopharmaceuticals. In: Inorganic Frameworks as Smart Nanomedicines. Mihai A (Eds). Elsevier, Oxford, UK, 565–603 (2018).
  Google Scholar
• 107 Turanlı ET, Everest E. Nanomedicine. In: Low-Dimensional and Nanostructured Materials and Devices. Ünlü H, Horing NJM, Dabrowski J (Eds). Springer International Publishing, NY, USA, 579–587 (2016).
  Google Scholar
• 108 Tinkle S, Mcneil SE, Mühlebach S et al. Nanomedicines: addressing the scientific and regulatory gap. Ann. N. Y. Acad. Sci. 1313(1), 35–56 (2014).
  Medline CASGoogle Scholar
• 109 Satalkar P, Elger BS, Hunziker P, Shaw D. Challenges of clinical translation in nanomedicine: a qualitative study. Nanomedicine 12(4), 893–900 (2016).
  Medline CASGoogle Scholar
• 110 Zamboni WC, Torchilin V, Patri AK et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin. Cancer Res. 18(12), 3229–3241 (2012).
  Medline CASGoogle Scholar
• 111 Satalkar P, Elger BS, Shaw D. Naming it ‘nano’: expert views on ‘nano’ terminology in informed consent forms of first-in-human nanomedicine trials. Nanomedicine 11(8), 933–940 (2016).
  CASGoogle Scholar
• 112 Allon I, Ben-Yehudah A, Dekel R, Solbakk J-H, Weltring K-M, Siegal G. Ethical issues in nanomedicine: tempest in a teapot? Med. Health Care Philos. 20(1), 3–11 (2017).
  MedlineGoogle Scholar
• 113 Beaudry C, Allaoui S. Impact of public and private research funding on scientific production: the case of nanotechnology. Res. Policy 41(9), 1589–1606 (2012).
  Google Scholar
• 114 Fatehi L, Wolf SM, Mccullough J et al. Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J. Law Med. Ethics 40(4), 716–750 (2012).
  MedlineGoogle Scholar
• 115 Graur F, Elisei R, Szasz A et al. Ethical issues in nanomedicine. In: International Conference on Advancements of Medicine and Health Care through Technology. Vlad S, Ciupa RV (Eds). Springer, Berlin, Heidelberg, 36, 9–12 (2011).
  Google Scholar
• 116 Wolf SM. Introduction: the challenge of nanomedicine human subjects research: protecting participants, workers, bystanders, and the environment. J. Law Med. Ethics 40(4), 712–715 (2012).
  MedlineGoogle Scholar
• 117 Hamburg MA. FDA's approach to regulation of products of nanotechnology. Science 336(6079), 299–300 (2012).
  Medline CASGoogle Scholar
• 118 Bawa R. FDA and Nanotech: baby steps lead to regulatory uncertainty. In: Bio-Nanotechnology: A Revolution in Food, Biomedical and Health Sciences. Bagchi D, Bagchi M, Moriyama H, Shahidi F (Eds). John Wiley & Sons, Ltd, Chichester, UK, 720–732 (2013).
  Google Scholar
• 119 Zolnik B, Potter TM, Stern ST. Detecting reactive oxygen species in primary hepatocytes treated with nanoparticles. Methods Mol. Biol. (Clifton, N.J.) 697(3), 173–179 (2011).
  Medline CASGoogle Scholar
• 120 Nowack B, Ranville JF, Diamond S et al. Potential scenarios for nanomaterial release and subsequent alteration in the environment. Environ. Toxicol. Chem. 31(1), 50–59 (2012).
  Medline CASGoogle Scholar
• 121 Louie SM, Ma R, Lowry GV, Gregory KB, Apte SC, Lead JR. Transformations of nanomaterials in the environment. Environ. Sci. Technol. 46(13), 6893–6899 (2012).
  MedlineGoogle Scholar
• 122 Bawa R. Regulating nanomedicine–can the FDA handle it? Curr. Drug Del. 8(3), 227–234 (2011). • Highlights the ongoing question of regulatiory authorities and nanomedicine.
  Medline CASGoogle Scholar
• 123 Gaspar R, Aksu B, Cuine A et al. Towards a European strategy for medicines research (2014–2020): the EUFEPS position paper on Horizon 2020. Eur. J. Pharm. Sci. 47(5), 979–987 (2012).
  Medline CASGoogle Scholar
• 124 European Medicines A. Questions and answers on biosimilar medicines (similar biological medicinal products). 44, 1–1 (2012). www.medicinesforeurope.com/2012/09/27/ema-questions-and-answers-on-biosimilar-medicines-similar-biological-medicinal-products/.
  Google Scholar
• 125 Schellekens H, Stegemann S, Weinstein V et al. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J. 16(1), 15–21 (2014).
  Medline CASGoogle Scholar
• 126 Andrews PLR, Kovacs M, Watson JW. The anti-emetic action of the neurokinin₁ receptor antagonist CP-99,994 does not require the presence of the area postrema in the dog. Neurosci. Lett. 314(1–2), 102–104 (2001).
  Medline CASGoogle Scholar
• 127 Emend^® (aprepitant) capsules, for oral use and oral suspension [Prescribing Information]. Merck & Co., Inc., NJ, USA (2015) .
  Google Scholar
• 128 Maggi CA. The mammalian tachykinin receptors. Gen. Pharmacol. 26(5), 911–944 (1995).
  Medline CASGoogle Scholar
• 129 Junghanns JUaH, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 3(3), 295–309 (2008).
  Medline CASGoogle Scholar
• 130 Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann. Oncol. 21(Suppl. 5), (2010).
  Google Scholar
• 131 Brandt J, Henning S, Michler G, Hein W, Bernstein A, Schulz M. Nanocrystalline hydroxyapatite for bone repair: an animal study. J. Mater. Sci. Mater. Med. 21(1), 283–294 (2010).
  Medline CASGoogle Scholar
• 132 Huber FX, Belyaev O, Hillmeier J et al. First histological observations on the incorporation of a novel nanocrystalline hydroxyapatite paste OSTIM^® in human cancellous bone. BMC Musculoskelet. Disord. 7(50), doi:10.1186/1471-2474-7-50 (2006).
  MedlineGoogle Scholar
• 133 Tadic D, Epple M. A thorough physicochemical characterisation of 14 calcium phosphate-based bone substitution materials in comparison to natural bone. Biomaterials 25(6), 987–994 (2004).
  Medline CASGoogle Scholar
• 134 Narayan R, Pednekar A, Bhuyan D, Gowda C, Koteshwara K, Nayak UY. A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies. Int. J. Nanomed. 12, 4921 (2017).
  Medline CASGoogle Scholar
• 135 Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res. 33(10), 2373–2387 (2016).
  Medline CASGoogle Scholar
• 136 Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm. 399(1–2), 129–139 (2010).
  Medline CASGoogle Scholar
• 137 Kesisoglou F, Panmai S, Wu Y. Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv. Drug Del. Rev. 59(7), 631–644 (2007).
  Medline CASGoogle Scholar
• 138 Sehgal SN. Rapamune^® (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 31(5), 335–340 (1998).
  Medline CASGoogle Scholar
• 139 Marya S, Ariyanayagam T, Chatterjee B, Toms AP, Crawford R. A prospective study of the efficacy of vitoss (beta tricalcium phosphate) as a bone graft substitute for instrumented posterolateral lumbar fusions. Spine J. 17(3), S23 (2017).
  Google Scholar
• 140 Campion CR, Ball SL, Clarke DL, Hing KA. Microstructure and chemistry affects apatite nucleation on calcium phosphate bone graft substitutes. J. Mater. Sci. Mater. Med. 24(3), 597–610 (2013).
  Medline CASGoogle Scholar
• 141 Bajwa S, Munawar A, Khan W. Nanotechnology in medicine: innovation to market. Pharm. Bioprocess. 5(2), 11–15 (2017).
  Google Scholar
• 142 Behabtu N, Young CC, Tsentalovich DE et al. Strong, light, multifunctional fibers of carbon nanotubes with ultrahigh conductivity. Science 339(6116), 182–186 (2013).
  Medline CASGoogle Scholar
• 143 Swanson JM, Wigal SB, Wigal T et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113(3), e206–e216 (2004).
  MedlineGoogle Scholar
• 144 Harris G. Warning urged on stimulants like Ritalin. New York Times 10 (2006).
  Google Scholar
• 145 Diller LH. The run on Ritalin: attention deficit disorder and stimulant treatment in the 1990s. Hastings Cent. Rep. 26(2), 12–18 (1996).
  Medline CASGoogle Scholar
• 146 Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. Atten. Defic. Hyperact. Disord. 2(4), 241–255 (2010).
  MedlineGoogle Scholar
• 147 Doward J, Craig E. Ritalin use for ADHD children soars fourfold. Observer 6 (2012).
  Google Scholar
• 148 Hunt RD. Functional roles of norepinephrine and dopamine in ADHD. Medscape Psychiatr. 11(1), 2006 (2006).
  Google Scholar
• 149 Arnsten AF, Li B-M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 57(11), 1377–1384 (2005).
  Medline CASGoogle Scholar
• 150 Markowitz J, Devane C, Ramamoorthy S, Zhu H-J. The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT1A receptor. Die Pharmazie 64(2), 123–125 (2009).
  Medline CASGoogle Scholar
• 151 Volkow ND, Wang G, Fowler JS et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 21(2), RC121 (2001).
  Medline CASGoogle Scholar
• 152 Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can. J. Clin. Pharmacol. 13(1), e50–e62 (2006).
  MedlineGoogle Scholar
• 153 Mott TF, Leach L. Is methylphenidate useful for treating adolescents with ADHD? J. Fam. Pract. 53(9), 650–663 (2004).
  MedlineGoogle Scholar
• 154 Handen BL, Feldman H, Gosling A, Breaux AM, Mcauliffe S. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 30(2), 241–245 (1991).
  Medline CASGoogle Scholar
• 155 Alagona P Jr. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc. Health Risk Manag. 6(1), 351–362 (2010).
  Medline CASGoogle Scholar
• 156 Tricor^® fenofibrate tablet [Prescribing Information], Abbott Laboratories, IL, USA (2010).
  Google Scholar
• 157 ‘Nanoparticle technology now allows TriCor(R) to be taken with or without food’. Abbott Laboratories Press Release (2004). www.abbottinvestor.com/news-releases/news-release-details/abbott-receives-fda-approval-new-formulation-tricorr-fenofibrate.
  Google Scholar
• 158 Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 380(6574), 561 (1996).
  Medline CASGoogle Scholar
• 159 Gill PS, Wernz J, Scadden DT et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14(8), 2353–2364 (1996).
  Medline CASGoogle Scholar
• 160 Andreopoulou E, Gaiotti D, Kim E et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil^®): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann. Oncol. 18(4), 716–721 (2007).
  Medline CASGoogle Scholar
• 161 Pillai G, Ceballos-Coronel ML. Science and technology of the emerging nanomedicines in cancer therapy: a primer for physicians and pharmacists. SAGE Open Med. 1, doi: 10.1177/2050312113513759 (2013).
  MedlineGoogle Scholar
• 162 Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4(3), 95 (2002).
  Medline CASGoogle Scholar
• 163 Gordon AN, Granai C, Rose PG et al. Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 18(17), 3093–3100 (2000).
  Medline CASGoogle Scholar
• 164 Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 16(3), 175–183 (2006).
  Medline CASGoogle Scholar
• 165 Murphy T, Yee KW. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opin. Pharmacother. 18(16), 1765–1780 (2017).
  Medline CASGoogle Scholar
• 166 [No authors listed]. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration. J. Int. Assoc. Phys. AIDS Care 2(5), 50–51 (1996).
  Google Scholar
• 167 Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk. Lymphoma 46(6), 795–802 (2005).
  Medline CASGoogle Scholar
• 168 Yarmolenko PS, Zhao Y, Landon C et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int. J. Hyperthermia 26(5), 485–498 (2010).
  Medline CASGoogle Scholar
• 169 Fosså S, Aass N, Parö G. A Phase II study of DaunoXome^® in advanced urothelial transitional cell carcinoma. Eur. J. Cancer 34(7), 1131–1132 (1998).
  Medline CASGoogle Scholar
• 170 Passero FC Jr, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev. Anticancer Ther. 16(7), 697–703 (2016).
  Medline CASGoogle Scholar
• 171 Digiulio S. FDA Approves onivyde combo regimen for advanced pancreatic cancer. Oncology Times (2015).
  Google Scholar
• 172 Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817–1825 (2011).
  Medline CASGoogle Scholar
• 173 Zhang H. Onivyde for the therapy of multiple solid tumors. Onco Targets Ther. 9, 3001 (2016).
  Medline CASGoogle Scholar
• 174 Mantripragada S. A lipid based depot (DepoFoam^® technology) for sustained release drug delivery. Prog. Lipid Res. 41(5), 392–406 (2002).
  Medline CASGoogle Scholar
• 175 Jaeckle KA, Batchelor T, O'day SJ et al. An open label trial of sustained-release cytarabine (DepoCyt^™) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neurooncol. 57(3), 231–239 (2002).
  MedlineGoogle Scholar
• 176 Pearce H, Winter M, Beck WT. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv. Enzyme Regul. 30, 357–373 (1990).
  Medline CASGoogle Scholar
• 177 Kim S, Chatelut E, Kim JC et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J. Clin. Oncol. 11(11), 2186–2193 (1993).
  Medline CASGoogle Scholar
• 178 Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto SI. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br. J. Haematol. 119(1), 106–108 (2002).
  MedlineGoogle Scholar
• 179 Galmarini CM, Thomas X, Calvo F et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 117(4), 860–868 (2002).
  Medline CASGoogle Scholar
• 180 Dawidczyk CM, Kim C, Park JH et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control. Rel. 187, 133–144 (2014).
  Medline CASGoogle Scholar
• 181 Harrison TS, Lyseng-Williamson KA. Vincristine sulfate liposome injection. Biodrugs 27(1), 69–74 (2013).
  Medline CASGoogle Scholar
• 182 Yang S-H, Lin C-C, Lin Z-Z, Tseng Y-L, Hong R-L. A Phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. Invest. New Drugs 30(1), 282–289 (2012).
  Medline CASGoogle Scholar
• 183 Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 54(11), 2830–2833 (1994).
  Medline CASGoogle Scholar
• 184 Thomas DA, Sarris AH, Cortes J et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106(1), 120–127 (2006).
  Medline CASGoogle Scholar
• 185 Takemoto K, Kanazawa K. AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy. J. Liposome Res. 27(3), 1–9 (2016).
  MedlineGoogle Scholar
• 186 Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations – Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet – against systemic murine aspergillosis. Antimicrob. Agents Chemother. 48(3), 1047–1050 (2004).
  Medline CASGoogle Scholar
• 187 Stone NRH, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome^®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 76(4), 485–500 (2016).
  Medline CASGoogle Scholar
• 188 Crain ML. Daunorubicin & CYTARABINE LIPOSome (Vyxeos^™). Oncology Times 40(10), 30 (2018).
  Google Scholar
• 189 Allen C. Why I'm holding onto hope for nano in oncology. Mol. Pharm. 13(8), 2603–2604 (2016).
  Medline CASGoogle Scholar
• 190 Waknine Y. Medscape. FDA approves new drug for hereditary angioedema (2011). www.medscape.com/viewarticle/748570.
  Google Scholar
• 191 Mayer L, Liboiron B, Xie S, Tardi P, Paulsen K, Chiarella M. VYXEOS^™(CPX-351) Significantly improves overall survival in Phase 3 high-risk AML trial, validating the CombiPlex technology and opening opportunities for novel combinations Lawrence Mayer, Barry Liboiron, Sherwin Xie and Paul Tardi, Kim Paulsen, Michael Chiarella and Arthur Louie. www.controlledreleasesociety.org/meetings/Documents/2016%20Abstracts/33.pdf.
  Google Scholar
• 192 Wu TC. On the development of antifungal agents: perspective of the US Food and Drug Administration. Clin. Infect. Dis. 19(Suppl. 1), S54–S58 (1994).
  MedlineGoogle Scholar
• 193 Camarata PJ, Dunn DL, Farney AC, Parker RG, Seljeskog EL. Continual intracavitary administration of amphotericin B as an adjunct in the treatment of aspergillus brain abscess: case report and review of the literature. Neurosurgery 31(3), 575–579 (1992).
  Medline CASGoogle Scholar
• 194 Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. Drugs of Today 40(2), 133–146 (2004).
  Medline CASGoogle Scholar
• 195 Bressler NM, Treatment of age-related macular degeneration with photodynamic therapy study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 119(2), 198–207 (2001).
  Medline CASGoogle Scholar
• 196 Liu R. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer. US Patent 5707608 (1998).
  Google Scholar
• 197 Rogers AH, Duker JS, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 110(7), 1315–1320 (2003).
  MedlineGoogle Scholar
• 198 Parodi MB, Iacono P, Spasse S, Ravalico G. Photodynamic therapy for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Am. J. Ophthalmol. 141(1), 123–128 (2006).
  MedlineGoogle Scholar
• 199 Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch. Clin. Exp. Ophthalmol. 241(11), 899–906 (2003).
  Medline CASGoogle Scholar
• 200 Hogan A, Behan U, Kilmartin DJ. Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br. J. Ophthalmol. 89(9), 1109–1111 (2005).
  Medline CASGoogle Scholar
• 201 Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J. Pharm. Sci. 105(2), 460–475 (2016).
  Medline CASGoogle Scholar
• 202 Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis. 13(11), 1323–1332 (2007).
  MedlineGoogle Scholar
• 203 Connock M, Tubeuf S, Malottki K et al. Certolizumab pegol (CIMZIA^®) for the treatment of rheumatoid arthritis. Health Technol. Assess. 14(Suppl 2), 1–10 (2010).
  Medline CASGoogle Scholar
• 204 Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228–238 (2007).
  Medline CASGoogle Scholar
• 205 Mease P, Fleischmann R, Deodhar AA et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis. 73(1), 48–55 (2013).
  MedlineGoogle Scholar
• 206 Landewé R, Braun J, Deodhar A et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann. Rheum. Dis. 73(1), 39–47 (2013).
  MedlineGoogle Scholar
• 207 Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J. Exp. Med. 206(9), 1839–1843 (2009).
  Medline CASGoogle Scholar
• 208 Stephan J, Vlekova V, Le Deist F et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J. Pediatrics 123(4), 564–572 (1993).
  Medline CASGoogle Scholar
• 209 Adagen^® (pegademase bovine) injection [Prescribing Information], Sigma-Tau Pharmaceuticals, Inc., MD, USA (2014).
  Google Scholar
• 210 Torres C. Rare opportunities appear on the horizon to treat rare diseases. Nat. Med. 16(3), 241–241 (2010).
  Medline CASGoogle Scholar
• 211 Joralemon MJ, Mcrae S, Emrick T. PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem. Commun. 46(9), 1377–1393 (2010).
  Medline CASGoogle Scholar
• 212 Davis S, Abuchowski A, Park YK, Davis FF. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin. Exp. Immunol. 46(3), 649–652 (1981).
  Medline CASGoogle Scholar
• 213 Greenwald RB, Choe YH, Mcguire J, Conover CD. Effective drug-delivery by PEGylated drug conjugates. Adv. Drug Del. Rev. 55(2), 217–250 (2003).
  Medline CASGoogle Scholar
• 214 Sheridan WP, Fox RM, Begley CG et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339(8794), 640–644 (1992).
  Medline CASGoogle Scholar
• 215 Curran MP, Goa KL. Pegfilgrastim. Drugs 62(8), 1207–1213 (2002).
  Medline CASGoogle Scholar
• 216 Alconcel SNS, Baas AS, Maynard HD. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym. Chem. 2(7), 1442–1448 (2011).
  CASGoogle Scholar
• 217 Piedmonte DM, Treuheit MJ. Formulation of Neulasta^®(pegfilgrastim). Adv. Drug Del. Rev. 60(1), 50–58 (2008).
  Medline CASGoogle Scholar
• 218 Milton HJ, Chess RB. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2(3), 214–221 (2003).
  MedlineGoogle Scholar
• 219 Oncaspar^® (pegaspargase) Intravenous or Intramuscular Injection [Prescribing Information], Enzon Pharmaceuticals Inc. (2006).
  Google Scholar
• 220 Graham ML. Pegaspargase: a review of clinical studies. Adv. Drug Del. Rev. 55(10), 1293–1302 (2003).
  Medline CASGoogle Scholar
• 221 Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2(5), 347–360 (2003).
  Medline CASGoogle Scholar
• 222 Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary 30(7), 388–393 (1995).
  Medline CASGoogle Scholar
• 223 Duncan R. Polymer therapeutics: top 10 selling pharmaceuticals–what next? J. Control. Release 190, 371–380 (2014).
  Medline CASGoogle Scholar
• 224 Fried MW, Shiffman ML, Rajender Reddy K et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975–982 (2002).
  Medline CASGoogle Scholar
• 225 Lau GKK, Piratvisuth T, Kang XL et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352(26), 2682–2695 (2005).
  Medline CASGoogle Scholar
• 226 Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771–782 (2008).
  Medline CASGoogle Scholar
• 227 Roelfsema F, Biermasz NR, Pereira AM, Romijn J. Nanomedicines in the treatment of acromegaly: Focus on pegvisomant. Int. J. Nanomed. 1(4), 385–398 (2006).
  Medline CASGoogle Scholar
• 228 Van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295), 1754–1759 (2001).
  Medline CASGoogle Scholar
• 229 Leonart LP, Tonin FS, Ferreira VL et al. Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine (2018).
  MedlineGoogle Scholar
• 230 Gragoudas ES, Adamis AP, Cunningham ETJ, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351(27), 2805–2816 (2004).
  Medline CASGoogle Scholar
• 231 Shukla D, Namperumalsamy P, Goldbaum M, Cunningham E Jr. Pegaptanib sodium for ocular vascular disease. Indian J. Ophthalmol. 55(6), 427–430 (2007).
  MedlineGoogle Scholar
• 232 Bunka DHJ, Platonova O, Stockley PG. Development of aptamer therapeutics. Curr. Opin. Pharmacol. 10(5), 557–562 (2010).
  Medline CASGoogle Scholar
• 233 Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5(2), 123–132 (2006).
  Medline CASGoogle Scholar
• 234 Mcgahan L. Continuous erythropoietin receptor activator (Mircera) for renal anemia. Issues Emerg. Health Technol. (113), 1–6 (2008).
  MedlineGoogle Scholar
• 235 Association EM. Scientific discussion: summary of product characteristics: MIRCERA (methoxy polyethyl-ene glycol-epoetin beta) (2008).
  Google Scholar
• 236 Frimat L, Mariat C, Landais P, Koné S, Commenges B, Choukroun G. Anaemia management with CERA in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. BMJ open 3(3), e001888 (2013).
  MedlineGoogle Scholar
• 237 Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68(5), 556–567 (2000).
  Medline CASGoogle Scholar
• 238 Jacobson IM, Brown RS, Freilich B et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46(4), 971–981 (2007).
  Medline CASGoogle Scholar
• 239 Manns M, Pockros P, Norkrans G et al. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J. Viral Hepat. 20(8), 524–529 (2013).
  Medline CASGoogle Scholar
• 240 Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR). Annual Congress (2009).
  Google Scholar
• 241 US Food and Drug Administration. Prescribing Information for KRYSTEXXA (TM): Savient Pharmaceuticals (2009). www.accessdata.fda.gov/drugsatfda_docs/label/2010/125293s0000lbl.pdf.
  Google Scholar
• 242 Food F. Drug Administration. Label and Approval History KRYSTEXXA BLA 125293 Savient Pharm (2010).
  Google Scholar
• 243 Alconcel SN, Baas AS, Maynard HD. FDA-approved poly (ethylene glycol)–protein conjugate drugs. Polym. Chem. 2(7), 1442–1448 (2011).
  CASGoogle Scholar
• 244 Biggers K, Scheinfeld N. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. Curr. Opin. Investig. Drugs 9(4), 422–429 (2008).
  Medline CASGoogle Scholar
• 245 Centonze D, Puma E, Saleri C et al. Pegylation and interferons in multiple sclerosis. Farmeconomia 17(Suppl. 2), 5–11 (2016).
  Google Scholar
• 246 Chaplin S, Gnanapavan S. Plegridy for the treatment of RRMS in adults. Prescriber 26(9), 29–31 (2015).
  Google Scholar
• 247 Idec B. Plegridy prescribing information (2015).
  Google Scholar
• 248 Turecek P, Romeder-Finger S, Apostol C et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII: C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia 22(6), 957–965 (2016).
  Medline CASGoogle Scholar
• 249 Konkle BA, Stasyshyn O, Chowdary P et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 126(9), 1078–1085 (2015).
  Medline CASGoogle Scholar
• 250 Grewal IS. Emerging Protein Biotherapeutics. CRC Press, FL, USA (2009).
  Google Scholar
• 251 Wolinsky JS, Narayana PA, O'Connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61(1), 14–24 (2007).
  Medline CASGoogle Scholar
• 252 Johnson KP. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev. Neurother. 12(4), 371–384 (2012).
  Medline CASGoogle Scholar
• 253 Mckeage K. Glatiramer acetate 40 mg/mL in relapsing-remitting multiple sclerosis: a review. CNS Drugs 29(5), 425–432 (2015).
  Medline CASGoogle Scholar
• 254 Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14593–14598 (2004).
  Medline CASGoogle Scholar
• 255 Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 4(4), 647–653 (2007).
  Medline CASGoogle Scholar
• 256 Berges R. Eligard^®: pharmacokinetics, effect on testosterone and psa levels and tolerability. Eur. Urol. Suppl. 4(5), 20–25 (2005).
  CASGoogle Scholar
• 257 Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 61(2), 25–31 (2003).
  MedlineGoogle Scholar
• 258 Wex J, Sidhu M, Odeyemi I, Abou-Setta AM, Retsa P, Tombal B. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation. Clinicoecon. Outcomes Res. 5, 257–269 (2013).
  MedlineGoogle Scholar
• 259 Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 55(1), 299–307 (1999).
  Medline CASGoogle Scholar
• 260 Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol. Dial. Transplant. 12(5), 961–964 (1997).
  Medline CASGoogle Scholar
• 261 Oka Y, Miyazaki M, Takatsu S et al. A review article: sevelamer hydrochloride and metabolic acidosis in dialysis patients. Cardiovasc. Hematol. Disord. Drug Targets 8(4), 283–286 (2008).
  Medline CASGoogle Scholar
• 262 Spaia S. Phosphate binders: sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia 15(Suppl. 1), 22–26 (2011).
  Medline CASGoogle Scholar
• 263 Buster JE. Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expert Opin. Pharmacother. 11(9), 1489–1499 (2010).
  Medline CASGoogle Scholar
• 264 Simon JA, Group FTES. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 13(2), 222–231 (2006).
  MedlineGoogle Scholar
• 265 Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261–1268 (2008).
  Medline CASGoogle Scholar
• 266 Yoo JW, Lee CH. Drug delivery systems for hormone therapy. J. Control. Rel. 112(1), 1–14 (2006).
  Medline CASGoogle Scholar
• 267 Rai MF, Pham CT. Intra-articular drug delivery systems for joint diseases. Curr. Opin. Pharmacol. 40, 67–73 (2018).
  Medline CASGoogle Scholar
• 268 Taylor N. Nonsurgical management of osteoarthritis knee pain in the older adult: an update. Rheum. Dis. Clin. North Am. 33(4), 41–51 (2018).
  Google Scholar
• 269 Byers-Kraus V, Aazami H, Mehra P et al. Synovial and systemic pharmacokinetics of triamcinolone acetonide following intra-articular injection of an extended release formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis. Osteoarthr. Cartil. 25, S431 (2017).
  Google Scholar
• 270 Adedoyin AA. Development of injectable, stimuli-responsive biomaterials as active scaffolds for applications in advanced drug delivery and osteochondral tissue regeneration (2018).
  Google Scholar
• 271 Abraxane^® for Injectable Suspension [Prescribing Information], Celgene Pharmaceutical Co. NJ, USA (2005).
  Google Scholar
• 272 Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol [19]. Nature 277(5698), 665–667 (1979).
  Medline CASGoogle Scholar
• 273 Sparreboom A, Scripture CD, Trieu V et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin. Cancer Res. 11(11), 4136–4143 (2005).
  Medline CASGoogle Scholar
• 274 Elsadek B, Kratz F. Impact of albumin on drug delivery – new applications on the horizon. J. Control. Release 157(1), 4–28 (2012).
  Medline CASGoogle Scholar
• 275 Jang K, Yoon S, Kim S-E et al. Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state. Drug Des. Devel. Ther. 8, 851 (2014).
  Medline CASGoogle Scholar
• 276 Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794–7803 (2005).
  Medline CASGoogle Scholar
• 277 Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247–1252 (2007).
  Medline CASGoogle Scholar
• 278 Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin. Biol. Ther. 9(11), 1445–1451 (2009).
  Medline CASGoogle Scholar
• 279 Kaminetzky D, Hymes KB. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2(4), 717–724 (2008).
  Medline CASGoogle Scholar
• 280 Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin. Oncol. 33(1 Suppl. 3), S11–S16 (2006).
  Medline CASGoogle Scholar
• 281 Duvic M. Bexarotene and DAB389IL-2 (Denileukin Diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clin. Lymphoma 1, S51–S55 (2000).
  MedlineGoogle Scholar
• 282 Schwab CL, English DP, Roque DM, Pasternak M, Santin AD. Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy 6(12), 1279–1293 (2014).
  CASGoogle Scholar
• 283 FDA. Rebinyn: Coagulation Factor IX (Recombinant), GlycoPEGylated (2017).
  Google Scholar
• 284 Woods GM, Dunn MW, Dunn AL. Emergencies in hemophilia. Clin. Pediatr. Emerg. Med. 19(2), 110–121 (2018).
  Google Scholar
• 285 Peters R, Harris T. Advances and innovations in haemophilia treatment. Nat. Rev. Drug Discov. 17(7), 493–508 (2018).
  Medline CASGoogle Scholar
• 286 Croteau SE. Evolving complexity in hemophilia management. Pediatr. Clin. North Am. 65(3), 407–425 (2018).
  MedlineGoogle Scholar
• 287 Farjadian F, Ghasemi S, Mohammadi-Samani S. Hydroxyl-modified magnetite nanoparticles as novel carrier for delivery of methotrexate. Int. J. Pharm. 504(1), 110–116 (2016).
  Medline CASGoogle Scholar
• 288 Majidi S, Zeinali Sehrig F, Samiei M et al. Magnetic nanoparticles: applications in gene delivery and gene therapy. Artif. Cells Nanomed. Biotechnol. 44(4), 1186–1193 (2016).
  Medline CASGoogle Scholar
• 289 Farjadian F, Moradi S, Hosseini M. Thin chitosan films containing super-paramagnetic nanoparticles with contrasting capability in magnetic resonance imaging. J. Mater. Sci. Mater. Med. 28(3), 47 (2017).
  MedlineGoogle Scholar
• 290 Coyne DW. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Expert Opin. Pharmacother. 10(15), 2563–2568 (2009).
  Medline CASGoogle Scholar
• 291 Schwenk MH. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy 30(1), 70–79 (2010).
  Medline CASGoogle Scholar
• 292 Curtis BM, Barrett BJ, Djurdjev O, Singer J, Levin A, Group C-CI. Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada. Am. J. Kidney Dis. 50(5), 733–742 (2007).
  Medline CASGoogle Scholar
• 293 Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am. J. Nephrol. 25(4), 400–410 (2005).
  Medline CASGoogle Scholar
• 294 Spinowitz BS, Schwenk MH, Jacobs PM et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int. 68(4), 1801–1807 (2005).
  Medline CASGoogle Scholar
• 295 Mccormack PL. Ferumoxytol. Drugs 72(15), 2013–2022 (2012).
  Medline CASGoogle Scholar
• 296 ETPN – Nanomedicine European Technology Platform. Src, Ncpm, Ncrd. Strategic agenda for EuroNanoMed. https://etp-nanomedicine.eu/about-nanomedicine/strategic-research-and-innovation-agenda/.
  Google Scholar
• 297 BCC Research. Global markets for nanoparticle size analysis instrumentation in the life sciences (2014). www.bccresearch.com/market-research/biotechnology/nanoparticle-size-analysis-instrumentation-life-sciences-report-bio114b.html.
  Google Scholar
• 298 Moghimi SM, Peer D, Langer R. Reshaping the future of nanopharmaceuticals: adiudicium. ACS nano 5(11), 8454–8458 (2011).
  Medline CASGoogle Scholar
• 299 Bowman D, Marino AD, Sylvester DJ. The patent landscape of nanomedicines. Med. Res. Arch. 5(9), (2017).
  Google Scholar
• 300 Business Wire. Global nanomedicine market analysis & trends report 2016 – market is poised to grow to reach approximately $1.3 trillion by 2025– research and markets (2016). www.businesswire.com/news/home/20160804005610/en/Global-Nanomedicine-Market-Analysis-Trends-Report-2016.
  Google Scholar
• 301 Ridings JE. The thalidomide disaster, lessons from the past. In: Teratogenicity Testing. Barrow PC (Ed.). Springer, Basel, Switzerland, 575–586 (2013).
  Google Scholar
• 302 Faunce T, Townsend R, Mcewan A. The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe & Dohme (Aust) Pty Ltd (2010) 184 FCR 1. J. Law Med. 18(1), 38–49 (2010).
  MedlineGoogle Scholar
• 303 Katz JA. COX-2 inhibition: what we learned–a controversial update on safety data. Pain Med. 14(Suppl. 1), S29–S34 (2013).
  MedlineGoogle Scholar
• 304 Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int. J. Nanomed. 9, 4357 (2014).
  Medline CASGoogle Scholar
• 305 Ledford H. Bankruptcy of nanomedicine firm worries drug developers. Nature 533(7603), 304–305 (2016).
  Medline CASGoogle Scholar
• 306 Adams DJ. The valley of death in anticancer drug development: a reassessment. Trends Pharmacol. Sci. 33(4), 173–180 (2012).
  Medline CASGoogle Scholar
• 307 Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano 7(9), 7442–7447 (2013).
  Medline CASGoogle Scholar
• 308 Prabhakar U, Maeda H, Jain RK et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73(8), 2412–2417 (2013).
  Medline CASGoogle Scholar
• 309 Rosenblum D, Peer D. Omics-based nanomedicine: the future of personalized oncology. Cancer Lett. 352(1), 126–136 (2014).
  Medline CASGoogle Scholar
• 310 Roointan A, Kianpour S, Memari F, Gandomani M, Gheibi Hayat SM, Mohammadi-Samani S. Poly(lactic-co-glycolic acid): the most ardent and flexible candidate in biomedicine! Int. J. Polym. Materi. Polym. Biomater. 67(17), 1028–1049 (2018).
  CASGoogle Scholar
• 311 Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomed. Nanotechnol. Biol. Med. 12(1), 81–103 (2016).
  CASGoogle Scholar
• 312 Eetezadi S, Ekdawi SN, Allen C. The challenges facing block copolymer micelles for cancer therapy: in vivo barriers and clinical translation. Adv. Drug Del. Rev. 91, 7–22 (2015).
  Medline CASGoogle Scholar
• 313 Gabizon A, Bradbury M, Prabhakar U, Zamboni W, Libutti S, Grodzinski P. Cancer nanomedicines: closing the translational gap. Lancet 384(9961), 2175–2176 (2014).
  MedlineGoogle Scholar
• 314 Lammers T. Smart drug delivery systems: back to the future vs. clinical reality. Int. J. Pharm. 454(1), 527–529 (2013).
  Medline CASGoogle Scholar
• 315 Satalkar P, Elger BS, Hunziker P, Shaw D. Challenges of clinical translation in nanomedicine: a qualitative study. Nanomedicine 12(4), 893–900 (2016).
  Medline CASGoogle Scholar
• 316 Kimmelman J. Beyond human subjects: risk, ethics, and clinical development of nanomedicines. J. Law Med. Ethics 40(4), 841–847 (2012).
  MedlineGoogle Scholar
• 317 Van De Poel I. How should we do nanoethics? A network approach for discerning ethical issues in nanotechnology. Nanoethics 2(1), 25–38 (2008).
  Google Scholar
• 318 Weissig V, Guzman-Villanueva D. Nanopharmaceuticals (part 2): products in the pipeline. Int. J. Nanomedicine 10, 1245–1257 (2015).
  Medline CASGoogle Scholar
• 319 Liang X-J. Nanopharmaceutics: The Potential Application of Nanomaterials. World Scientific Publishing Co., Pte Ltd, Toh Tuck Link, Singapore (2013).
  Google Scholar
• 320 Shah RB, Khan MA. Nanopharmaceuticals: challenges and regulatory perspective. In: Nanotechnology in Drug Delivery. de Villiers MM, Aramwit P, Kwon GS (Eds). Springer, NY, USA (2009).
  Google Scholar
• 321 Eaton MA. How do we develop nanopharmaceuticals under open innovation? Nanomedicine 7(4), 371–375 (2011).
  MedlineGoogle Scholar